

## Michael Rowley Publications

1. Jones, P.; Wilcoxon, K.; Rowley, M.; Toniatti, C. (2015) Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination *J. Med. Chem.*, 58, 3302-3314.
2. Summa, V.; Ludmerer, S.W.; McCauley, J.A.; Fandozzi, C.; Burlein, C.; Claudio, G.; Coleman, P. J.; DiMuzio, J.M.; Ferrara, M.; Di Filippo, M.; Gates, A. T.; Graham, D.J.; Harper, S.; Hazuda, D. J.; McHale, C.; Monteagudo, E.; Pucci, V.; Rowley, M.; Rudd, M. T.; Soriano, A.; Stahlhut, M. W.; Vacca, J.P.; Olsen, D.B.; Liverton, N.J.; Carroll, S.S. (2012) MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. *Antimicrob. Agents and Chemother.*, 56, 4161-4167.
3. Rudd, M. T.; McIntyre, C.J.; Romano, J.J.; Butcher, J.W.; Holloway, M. K.; Bush, K.; Nguyen, K.T.; Gilbert, K.F.; Lyle, T.A.; Liverton, N.J.; Wan, B.-L.; Summa, V.; Harper, S.; Rowley, M.; Vacca, J.P.; Carroll, S.S.; Burlein, C.; DiMuzio, J.M.; Gates, A.; Graham, D.J.; Huang, Q.; Ludmerer, S.W.; McClain, S.; McHale, C.; Stahlhut, M.; Fandozzi, C.; Taylor, A.; Trainor, N.; Olsen, D.B.; McCauley, J.A. (2012) Development of macrocyclic inhibitors of HCV NS3/4A protease with cyclic constrained P2-P4 linkers. *Bioorg. Med. Chem. Lett.*, 22, 7207-7213.
4. Rudd, M. T.; McCauley, J.A.; Romano, J.J.; Butcher, J.W.; Bush, K.; McIntyre, C.J.; Nguyen, K.T.; Gilbert, K.F.; Lyle, T.A.; Holloway, M. K.; Wan, B.-L.; Vacca, J.P.; Summa, V.; Harper, S.; Rowley, M.; Carroll, S.S.; Burlein, C.; DiMuzio, J.M.; Gates, A.; Graham, D.J.; Huang, Q.; Ludmerer, S.W.; McClain, S.; McHale, C.; Stahlhut, M.; Fandozzi, C.; Taylor, A.; Trainor, N.; Olsen, D.B.; Liverton, N.J. (2012) Development of potent macrocyclic inhibitors of genotype 3a HCV NS3/4A protease. *Bioorg. Med. Chem. Lett.*, 22, 7201-7206.
5. Harper, S.; McCauley, J.A.; Rudd, M.T.; Ferrara, M.; DiFilippo, M.; Crescenzi, B.; Koch, B.; Petrocchi, A.; Holloway, M.K.; Butcher, J.W.; Romano, J.J.; Bush, K.J.; Gilbert, K.F.; McIntyre, C.J.; Nguyen, K.T.; Nizi, E.; Carroll, S.S.; Ludmerer, S.W.; Burlein, C.; DiMuzio, J.M.; Graham, D.J.; McHale, C.M.; Stahlhut, M.W.; Olsen, D.B.; Monteagudo, E.; Cianetti, S.; Giuliano, C.; Pucci, V.; Trainor, N.; Fandozzi, C.M.; Rowley, M.; Coleman, P.J.; Vacca, J.P.; Summa, V.; Liverton, N.J. (2012) Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor. *ACS Med. Chem. Lett.*, 3, 332-336
6. Di Francesco, M. E.; Avolio, S.; Pompei, M.; Pesci, S.; Monteagudo, E.; Pucci, V.; Giuliano, C.; Fiore, F.; Rowley, M.; Summa, V. (2012) Synthesis and antiviral properties of novel 7-heterocyclic substituted 7-deaza-adenine nucleoside inhibitors of Hepatitis C NS5B polymerase. *Bioorg. Med. Chem.*, 20, 4801-481.
7. Di Francesco, M. E.; Avolio, S.; Dessole, G.; Koch, U.; Pompei, M.; Pucci, V.; Rowley, M.; Summa, V. (2012) Synthesis and Antiviral Properties of Novel Tetracyclic Nucleoside Inhibitors of Hepatitis C NS5B Polymerase. *Nucleosides, Nucleotides & Nucleic Acids*, 31, 592-607.
8. Rowley, M. (2012) Antiviral Drugs: From Basic Discovery Through Clinical Trials Edited by Wieslaw M. Kazmierski. *ChemMedChem* 7, 172.

9. Gabrielsson, J.; Fjellstrom, O.; Ulander, J.; Rowley, M.; Van Der Graaf, P.H. (2011) Pharmacodynamic-pharmacokinetic integration as a guide to medicinal chemistry. *Curr. Topics Med. Chem.*, 11, 404-18.
10. Muraglia, E.; Ontoria, J.M.; Branca, D.; Dessole, G.; Bresciani, A.; Fonsi, M.; Giuliano, C.; Llauger Bufi, L.; Monteagudo, E.; Palumbi, M.C.; Rowley, M.; Jones, P. (2011) N-(2-alkylaminoethyl)-4-(1,2,4-oxadiazol-5-yl)piperazine-1-carboxamides as highly potent smoothed antagonists. *Bioorg. Med. Chem. Lett.*, 21, 5283-5288.
11. Ontoria, J.M.; Llauger Bufi, L.; Torrisi, C.; Bresciani, A.; Giomini, C.; Rowley, M.; Serafini, S.; Bin, H.; Hao, W.; Steinkuehler, C.; Jones, P. (2011) Identification of a series of 4-[3-(quinolin-2-yl)-1,2,4-oxadiazol-5-yl]piperazinyl ureas as potent smoothed antagonist hedgehog pathway inhibitors. *Bioorg. Med. Chem. Lett.*, 21, 5274-5282.
12. Kinzel, O.; Alfieri, A.; Altamura, S.; Brunetti, M.; Bufali, S.; Colaceci, F.; Ferrigno, F.; Filocamo, G.; Fonsi, M.; Gallinari, P.; Rowley, M.; Jones, P. (2011) Identification of MK-5710 ((8aS)-8a-methyl-1,3-dioxo-2-[(1S,2R)-2-phenylcyclopropyl]-N-(1-phenyl-1H-pyrazol-5-yl)hexahydroimidazo[1,5-a]pyrazine-7(1H)-carboxamide), a potent smoothed antagonist for use in Hedgehog pathway dependent malignancies, Part 2. *Bioorg. Med. Chem. Lett.*, 21, 4429-4435.
13. Malancona, S.; Altamura, S.; Filocamo, G.; Kinzel, O.; Hernando, J.I.M.; Rowley, M.; Scarpelli, R.; Steinkuehler, C.; Jones, P. (2011) Identification of MK-5710 ((8aS)-8a-methyl-1,3-dioxo-2-[(1S,2R)-2-phenylcyclopropyl]-N-(1-phenyl-1H-pyrazol-5-yl)hexahydroimidazo[1,5-a]pyrazine-7(1H)-carboxamide), a potent smoothed antagonist for use in Hedgehog pathway dependent malignancies, Part 1. *Bioorg. Med. Chem. Lett.*, 21, 4422-4428.
14. Nguyen B.-Y.T.; Isaacs R.D; Teppler H.; Leavitt R.Y.; Sklar P.; Iwamoto M.; Wenning L.A.; Miller M.D.; Chen J.; Kemp R.; Xu W.; Fromtling R.A.; Vacca J.P.; Young S.D.; Rowley M.; Lower M.W.; Gottesdiener K.M.; Hazuda D.J. (2011) Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium. *Annals New York Acad. Sci.*, 1222(1), 83-9.
15. Narjes, F.; Crescenzi, B.; Ferrara, M.; Habermann, J.; Colarusso, S.; Rico Ferreira, M.; Stansfield, I.; Mackay, A.C.; Conte, I.; Ercolani, C.; Zaramella, S.; Palumbi, M.-C.; Meuleman, P.; Leroux-Roels, G.; Giuliano, C.; Fiore, F.; Di Marco, S.; Baiocco, P.; Koch, U.; Migliaccio, G.; Altamura, S.; Laufer, R.; De Francesco, R.; Rowley, M. (2011) Discovery of (7R)-14-Cyclohexyl-7-{{2-(dimethylamino)ethyl}(methyl amino)}-7,8-dihydro-6H-indolo[1,2-e][1,5]benzoxazocine-11-carboxylic Acid (MK-3281), a Potent and Orally Bioavailable Finger-Loop Inhibitor of the Hepatitis C Virus NS5B Polymerase. *J. Med. Chem.*, 54, 289-301
16. Monteagudo, E.; Fonsi, M.; Chu, X.; Bleasby, K.; Evers, R.; Pucci, V.; Orsale, M. V.; Cianetti, S.; Ferrara, M.; Harper, S.; Rowley, M.; Summa, V. (2011) The metabolism and disposition of a potent inhibitor of hepatitis C virus NS3/4A protease. *Xenobiotica*, 40, 826-839.
17. Malancona, S.; Donghi, M.; Ferrara, M.; Martin Hernando, J.I.; Pompei, M.; Pesci, S.; Ontoria, J.M.; Koch, U.; Rowley, M.; Summa, V. (2010) Allosteric inhibitors of hepatitis C virus NS5B polymerase thumb domain site II: Structure-based design and synthesis of new templates. *Bioorg. Med. Chem.* 18, 2836-2848.

18. Ferrigno, F.; Branca, D.; Kinzel, O.; Lillini, S.; Llauger Bufi, L.; Monteagudo, E.; Muraglia, E.; Rowley, M.; Schultz-Fademrecht, C.; Toniatti, C. (2010) Development of substituted 6-[4-fluoro-3-(piperazin-1-ylcarbonyl)benzyl]-4,5-dimethylpyridazin-3(2H)-ones as potent poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors active in BRCA deficient cells. *Bioorg. Med. Chem. Lett.*, 20, 1100-1105.
19. Torrise, C.; Bisbocci, M.; Ingenito, R.; Ontoria, J.M.; Rowley, M.; Schultz-Fademrecht, C.; Toniatti, C.; Jones, P. (2010) Discovery and SAR of novel, potent and selective hexahydrobenzophenanthridinone inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1) *Bioorg. Med. Chem. Lett.*, 20, 448-452.
20. Cianetti S.; Cooper V.B.; Attenni B.; Pucci V.; Fiore F.; Giuliano C.; Laufer R.; Gardelli C.; Monteagudo E.; Narjes F.; Rowley, M. (2010) Enhancement of intestinal absorption of 2-methyl cytidine prodrugs. *Drug Delivery* 17, 214-22.
21. Pescatore, G.; Branca, D.; Fiore, F.; Kinzel, O.; Llauger Bufi, L.; Muraglia, E.; Orvieto, F.M.; Rowley, M.; Toniatti, C.; Torrise, C.; et al (2010) Identification and SAR of novel pyrrolo[1,2-a]pyrazin-1(2H)-one derivatives as inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1) *Bioorg. Med. Chem. Lett.*, 20, 1094-1099.
22. Scarpelli, R.; Boueres, J.K.; Cerretani, M.; Ferrigno, F.; Ontoria, J.M.; Rowley, M.; Schultz-Fademrecht, C.; Toniatti, C.; Jones, P. (2010) Synthesis and biological evaluation of substituted 2-phenyl-2H-indazole-7-carboxamides as potent poly(ADP-ribose) polymerase (PARP) inhibitors *Bioorg. Med. Chem. Lett.*, 20, 488-492.
23. Jones, P.; Altamura, S.; Boueres, J.; Ferrigno, F.; Fonsi, M.; Giomini, C.; Lamartina, S.; Monteagudo, E.; Ontoria, J. M.; Orsale, M. V.; Palumbi, M. C.; Pesci, S.; Roscilli, G.; Scarpelli, R.; Schultz-Fademrecht, C.; Toniatti, C.; Rowley, M. (2009) Discovery of 2-{4-[(3S)-Piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and -2 Mutant Tumors. *J. Med. Chem.*, 52, 7170-7185.
24. Di Francesco, M. E.; Dessole, G.; Nizi, E.; Pace, P.; Koch, U.; Fiore, F.; Pesci, S.; Di Muzio, J.; Monteagudo, E.; Rowley, M.; Summa, V. (2009) Novel macrocyclic inhibitors of Hepatitis C NS3/4A protease featuring a 2-amino-1,3-thiazole as a P4 carbamate replacement. *J. Med. Chem.*, 52(22), 7014-7028.
25. Ontoria, J. M.; Altamura, S.; Di Marco, A.; Ferrigno, F.; Laufer, R.; Muraglia, E.; Palumbi, M. C.; Rowley, M.; Scarpelli, R.; Schultz-Fademrecht, C.; Serafini, S.; Steinkuhler, C.; Jones, P. (2009) Identification of Novel, Selective, and Stable Inhibitors of Class II Histone Deacetylases: Validation Studies of the Inhibition of the Enzymatic Activity of HDAC4 by Small Molecules as a Novel Approach for Cancer Therapy. *J. Med. Chem.*, 52, 6782-6789.
26. Schultz-Fademrecht, C.; Kinzel, O.; Marko, I. E.; Pospisil, T.; Pesci, S.; Rowley, M.; Jones, P. (2009) A general approach to homochiral  $\alpha$ -amino substituted bromo-heteroaromatics suitable for two-dimensional rapid analogue synthesis. *Tetrahedron*, 9487-9493.
27. Martin Hernando, J. I.; Ontoria, J. M.; Malancona, S.; Attenni, B.; Fiore, F.; Bonelli, F.; Koch, U.; Di Marco, S.; Colarusso, S.; Ponzi, S.; Gennari, N.; Vignetti, S. E.; Rico Ferreira, M. del R.; Habermann, J.; Rowley, M.; Narjes, F. (2009) Optimization of Thienopyrrole-Based Finger-Loop Inhibitors of the Hepatitis C Virus NS5B Polymerase. *ChemMedChem*, 4, 1695-1713.

28. Fonsi, M.; Fiore, F.; Jones, P.; Kinzel, O.; Laufer, R.; Rowley, M.; Monteagudo, E. (2009) Metabolism-related liabilities of a potent histone deacetylase (HDAC) inhibitor and relevance of the route of administration on its metabolic fate. *Xenobiotica*, 39, 722-737.
29. Gardelli, C.; Attenni, B.; Donghi, M.; Meppen, M.; Pacini, B.; Harper, S.; Di Marco, A.; Fiore, F.; Giuliano, C.; Pucci, V.; Laufer, R.; Gennari, N.; Marcucci, I.; Leone, J. F.; Olsen, D. B.; MacCoss, M.; Rowley, M.; Narjes, F. (2009) Phosphoramidate Prodrugs of 2'-C-Methylcytidine for Therapy of Hepatitis C Virus Infection. *J. Med. Chem.*, 52, 5394-5407.
30. Ontoria, J. M.; Rydberg, E. H.; Di Marco, S.; Tomei, L.; Attenni, B.; Malancona, S.; Martin Hernando, J. I.; Gennari, N.; Koch, U.; Narjes, F.; Rowley, M.; Summa, V.; Carroll, S. S.; Olsen, D. B.; De Francesco, R.; Altamura, S.; Migliaccio, G.; Carfi, A. (2009) Identification and Biological Evaluation of a Series of 1H-Benzo[de]isoquinoline-1,3(2H)-diones as Hepatitis C Virus NS5B Polymerase Inhibitors. *J. Med. Chem.*, 52, 5217-5227.
31. Harper, S.; Ferrara, M.; Crescenzi, B.; Pompei, M.; Palumbi, M. C.; Di Muzio, J. M.; Donghi, M.; Fiore, F.; Koch, U.; Liverton, N. J.; Pesci, S.; Petrocchi, A.; Rowley, M.; Summa, V.; Gardelli, C. (2009) Inhibitors of the Hepatitis C Virus NS3 Protease with Basic Amine Functionality at the P3-Amino Acid N-Terminus: Discovery and Optimization of a New Series of P2-P4 Macrocycles. *J. Med. Chem.*, 52, 4820-4837.
32. Meppen, M.; Pacini, B.; Bazzo, R.; Koch, U.; Leone, J. F.; Koeplinger, K. A.; Rowley, M.; Altamura, S.; Di Marco, A.; Fiore, F.; Giuliano, C.; Gonzalez-Paz, O.; Laufer, R.; Pucci, V.; Narjes, F.; Gardelli, C. (2009) Cyclic phosphoramidates as prodrugs of 2'-C-methylcytidine. *Eur. J. Med. Chem.*, 44, 3765-3770.
33. Petrocchi, A.; Jones, P.; Rowley, M.; Fiore, F.; Summa, V. (2009) N-(4-Fluorobenzyl)-3-hydroxy-9,9-dimethyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrazino[1,2-a]pyrimidine-2-carboxamides a novel class of potent HIV-1 integrase inhibitors. *Bioorg. Med. Chem. Lett.* 19, 4245-4249.
34. Orvieto, F.; Branca, D.; Giomini, C.; Jones, P.; Koch, U.; Ontoria, J. M.; Palumbi, M. C.; Rowley, M.; Toniatti, C.; Muraglia, E. (2009) Identification of substituted pyrazolo[1,5-a]quinazolin-5(4H)-one as potent poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors. *Bioorg. Med. Chem. Lett.* 19, 4196-4200.
35. Dessole, G.; Branca, D.; Ferrigno, F.; Kinzel, O.; Muraglia, E.; Palumbi, M. C.; Rowley, M.; Serafini, S.; Steinkuehler, C.; Jones, P. (2009) Discovery of N-[(1-aryl-1H-indazol-5-yl)methyl]amides derivatives as Smoothened antagonists for inhibition of the hedgehog pathway. *Bioorg. Med. Chem. Lett.* 19 4191-4195.
36. Branca, D.; Cerretani, M.; Jones, P.; Koch, U.; Orvieto, F.; Palumbi, M. C.; Rowley, M.; Toniatti, C.; Muraglia, E. (2009) Identification of aminoethyl pyrrolo dihydroisoquinolinones as novel poly(ADP-ribose) polymerase-1 inhibitors. *Bioorg. Med. Chem. Lett.* 19, 4042-4045.
37. Attenni, B.; Ontoria, J. M.; Cruz, J. C.; Rowley, M.; Schultz-Fademrecht, C.; Steinkuehler, C.; Jones, P. (2009) Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model. *Bioorg. Med. Chem. Lett.* 19, 3081-3084.

38. Kinzel, O.; Llauger-Bufí, L.; Pescatore, G.; Rowley, M.; Schultz-Fademrecht, C.; Monteagudo, E.; Fonsi, M.; Gonzalez Paz, O.; Fiore, F.; Steinkuhler, C.; Jones, P. (2009) Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties. *J. Med. Chem.*, 52, 3453-3456.
39. Laufer, R.; Paz, O. Gonzalez; Di Marco, A.; Bonelli, F.; Monteagudo, E.; Summa, V.; Rowley, M. (2009) Quantitative prediction of human clearance guiding the development of raltegravir (MK-0518, Isentress) and related HIV integrase inhibitors. *Drug Met. Disp.* 37, 873-883.
40. Conte, I.; Giuliano, C.; Ercolani, C.; Narjes, F.; Koch, U.; Rowley, M.; Altamura, S.; De Francesco, R.; Neddermann, P.; Migliaccio, G.; Stansfield, I. (2009) Synthesis and SAR of piperazinyl-N-phenylbenzamides as inhibitors of hepatitis C virus RNA replication in cell culture. *Bioorg. Med. Chem. Lett.* 19, 1779-1783.
41. Donghi, M.; Attenni, B.; Gardelli, C.; Di Marco, A.; Fiore, F.; Giuliano, C. (2009) Synthesis and evaluation of novel phosphoramidate prodrugs of 2'-methyl cytidine as inhibitors of hepatitis C virus NS5B polymerase. *Bioorg. Med. Chem. Lett.* 19, 1392-1395.
42. Stansfield, I.; Ercolani, C.; Mackay, A.; Conte, I.; Pompei, M.; Koch, U.; Gennari, N.; Giuliano, C.; Rowley, M.; Narjes, F. (2009) Tetracyclic indole inhibitors of hepatitis C virus NS5B-polymerase. *Bioorg. Med. Chem. Lett.* 19, 627-632.
43. Orvieto F.; Branca D.; Giomini C.; Jones P.; Koch U.; Ontoria J. M.; Palumbi M. C.; Rowley M.; Toniatti C.; Muraglia E. (2009) Identification of substituted pyrazolo[1,5-a]quinazolin-5(4H)-one as potent poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors. *Bioorg. Med. Chem. Lett.* 19, 4196-200.
44. Kinzel, O.; Llauger-Bufí, L.; Pescatore, G.; Rowley M.; Schultz-Fademrecht, C.; Monteagudo, E.; Fonsi, M.; Gonzalez Pa, O.; Fior, F.; Steinkuhle, C.; Jones P. (2009) Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties. *J. Med. Chem.* 52, 3453-6.
45. Rowley, M. (2008) The discovery of raltegravir, an integrase inhibitor for the treatment of HIV infection. *Progress in Medicinal Chemistry*, 46, 1-28. Eds. Lawton, G; Witty, D. Elsevier B.V., Amsterdam.
46. Muraglia, E.; Altamura, S.; Branca, D.; Cecchetti, O.; Ferrigno, F.; Orsale, M. V.; Palumbi, M. C.; Rowley, M.; Scarpelli, R.; Steinkuhler, C.; Jones, P. (2008) 2-Trifluoroacetylthiophene oxadiazoles as potent and selective class II human histone deacetylase inhibitors. *Bioorg. Med. Chem. Lett.* 18, 6083-6087.
47. Scarpelli, R.; Di Marco, A.; Ferrigno, F.; Laufer, R.; Marcucci, I.; Muraglia, E.; Ontoria, J. M.; Rowley, M.; Serafini, S.; Steinkuhler, C.; Jones, P. (2008) Studies of the metabolic stability in cells of 5-(trifluoroacetyl)thiophene-2-carboxamides and identification of more stable class II histone deacetylase (HDAC) inhibitors. *Bioorg. Med. Chem. Lett.* 18, 6078-6082.
48. Pescatore, G.; Kinzel, O.; Attenni, B.; Cecchetti, O.; Fiore, F.; Fonsi, M.; Rowley, M.; Schultz-Fademrecht, C.; Serafini, S.; Steinkuehler, C.; Jones, P. (2008) Optimization of a series of potent and selective ketone histone deacetylase inhibitors. *Bioorg. Med. Chem. Lett.* 18, 5528-5532.

49. Kinzel, O. D.; Ball, R. G.; Donghi, M.; Maguire, C. K.; Muraglia, E.; Pesci, S.; Rowley, M.; Summa, V. (2008) 3-Hydroxy-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxylates-fast access to a heterocyclic scaffold for HIV-1 integrase inhibitors. *Tet. Lett.* 49, 6556-6558.
50. Summa, V.; Petrocchi, A.; Bonelli, F.; Crescenzi, B.; Donghi, M.; Ferrara, M.; Fiore, F.; Gardelli, C.; Gonzalez Paz, O.; Hazuda, D. J.; Jones, P.; Kinzel, O.; Laufer, R.; Monteagudo, E.; Muraglia, E.; Nizi, E.; Orvieto, F.; Pace, P.; Pescatore, G.; Scarpelli, R.; Stillmock, K.; Witmer, M. V.; Rowley, M. (2008) Discovery of Raltegravir, a Potent, Selective Orally Bioavailable HIV-Integrase Inhibitor for the Treatment of HIV-AIDS Infection. *J. Med. Chem.*, 51, 5843-5855.
51. Pace, Paola; Rowley, M. (2008) Integrase inhibitors for the treatment of HIV infection. *Current Opinion in Drug Discovery & Development* 11, 471-479.
52. Jones, P.; Bottomley, M. J.; Carfi, A.; Cecchetti, O.; Ferrigno, F.; Lo Surdo, P.; Ontoria, J. M.; Rowley, M.; Scarpelli, R.; Schultz-Fademrecht, C.; Steinkuhler, C. (2008) 2-Trifluoroacetylthiophenes, a novel series of potent and selective class II histone deacetylase inhibitors. *Bioorg. Med. Chem. Lett.* 18, 3456-3461.
53. Di Francesco, M. E.; Pace, P.; Fiore, F.; Naimo, F.; Bonelli, F.; Rowley, M.; Summa, V. (2008) Development of 2-t-butyl-N-methyl pyrimidones as potent inhibitors of HIV integrase. *Bioorg. Med. Chem. Lett.* 18, 2709-2713.
54. Jones, P.; Altamura, S.; De Francesco, R.; Gonzalez Paz, O.; Kinzel, O.; Mesiti, G.; Monteagudo, E.; Pescatore, G.; Rowley, M.; Verdirame, M.; Steinkuhler, C. (2008) A Novel Series of Potent and Selective Ketone Histone Deacetylase Inhibitors with Antitumor Activity in Vivo. *J. Med. Chem.* 51, 2350-2353.
55. Jones, P.; Altamura, S.; De Francesco, R.; Gallinari, P.; Lahm, A.; Neddermann, P.; Rowley, M.; Serafini, S.; Steinkuehler, C. (2008) Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases. *Bioorg. Med. Chem. Lett.* 18, 1814-1819.
56. Muraglia, E.; Kinzel, O.; Gardelli, C.; Crescenzi, B.; Donghi, M.; Ferrara, M.; Nizi, E.; Orvieto, F.; Pescatore, G.; Laufer, R.; Gonzalez-Paz, O.; Di Marco, A.; Fiore, F.; Monteagudo, E.; Fonsi, M.; Felock, P. J.; Rowley, M.; Summa, V. (2008) Design and Synthesis of Bicyclic Pyrimidinones as Potent and Orally Bioavailable HIV-1 Integrase Inhibitors. *J. Med. Chem.* 51, 861-874.
57. Gardelli, C.; Nizi, E.; Muraglia, E.; Crescenzi, B.; Ferrara, M.; Orvieto, F.; Pace, P.; Pescatore, G.; Poma, M.; del Rosario Rico Ferreira, M.; Scarpelli, R.; Homnick, C. F.; Ikemoto, N.; Alfieri, A.; Verdirame, M.; Bonelli, F.; Gonzalez Paz, O.; Taliani, M.; Monteagudo, E.; Pesci, S.; Laufer, R.; Felock, P.; Stillmock, K. A.; Hazuda, D.; Rowley, M.; Summa, V. (2007) Discovery and Synthesis of HIV Integrase Inhibitors: Development of Potent and Orally Bioavailable N-Methyl Pyrimidones. *J. Med. Chem.* 50, 4953-4975.
58. Kinzel, O. D.; Monteagudo, E.; Muraglia, E.; Orvieto, F.; Pescatore, G.; del Rosario Rico Ferreira, M.; Rowley, M.; Summa, V. (2007) The synthesis of tetrahydropyridopyrimidones as a new scaffold for HIV-1 integrase inhibitors. *Tet. Lett.* 48, 6552-6555.
59. Stansfield, I.; Pompei, M.; Conte, I.; Ercolani, C.; Migliaccio, G.; Jairaj, M.; Giuliano, C.; Rowley, M.; Narjes, F. (2007) Development of carboxylic acid replacements in indole-N-

acetamide inhibitors of hepatitis C virus NS5B polymerase. *Bioorg. Med. Chem. Lett.* 17, 5143-5149.

60. Pace, P.; Di Francesco, M. E.; Gardelli, C.; Harper, S.; Muraglia, E.; Nizi, E.; Orvieto, F.; Petrocchi, A.; Poma, M.; Rowley, M.; Scarpelli, R.; Laufer, R.; Gonzalez Paz, O.; Monteagudo, E.; Bonelli, F.; Hazuda, D.; Stillmock, K. A.; Summa, V. (2007) Dihydroxypyrimidine-4-carboxamides as Novel Potent and Selective HIV Integrase Inhibitors. *J. Med. Chem.* 50, 2225-2239.
61. Jones, P.; Altamura, S.; Chakravarty, P. K.; Cecchetti, O.; De Francesco, R.; Gallinari, P.; Ingenito, R.; Meinke, P. T.; Petrocchi, A.; Rowley, M.; Scarpelli, R.; Serafini, S.; Steinkuehler, C. (2006) A series of novel, potent, and selective histone deacetylase inhibitors. *Bioorg. Med. Chem. Lett.* 16, 5948-5952.
62. Summa, V.; Petrocchi, A.; Matassa, V. G.; Gardelli, C.; Muraglia, E.; Rowley, M.; Paz, O. G.; Laufer, R.; Monteagudo, E.; Pace, P. (2006) 4,5-Dihydroxypyrimidine Carboxamides and N-Alkyl-5-hydroxypyrimidinone Carboxamides Are Potent, Selective HIV Integrase Inhibitors with Good Pharmacokinetic Profiles in Preclinical Species. *J. Med. Chem.* 49, 6646-6649.
63. Ontoria, J. M.; Martin Hernando, J. I.; Malancona, S.; Attenni, B.; Stansfield, I.; Conte, I.; Ercolani, C.; Habermann, J.; Ponzi, S.; Di Filippo, M.; Koch, U.; Rowley, M.; Narjes, F. (2006) Identification of thieno[3,2-b]pyrroles as allosteric inhibitors of hepatitis C virus NS5B polymerase. *Bioorg. Med. Chem. Lett.* 16, 4026-4030.
64. Muraglia, E.; Kinzel, O. D.; Laufer, R.; Miller, M. D.; Moyer, G.; Munshi, V.; Orvieto, F.; Palumbi, M. C.; Pescatore, G.; Rowley, M.; Williams, P. D.; Summa, V. (2006) Tetrazole thioacetanilides: Potent non-nucleoside inhibitors of WT HIV reverse transcriptase and its K103N mutant. *Bioorg. Med. Chem. Lett.* 16, 2748-2752
65. Di Marco, S.; Volpari, C.; Tomei, L.; Altamura, S.; Harper, S.; Narjes, F.; Koch, U.; Rowley, M.; De Francesco, R.; Migliaccio, G.; Carfi, A. (2005) Interdomain Communication in Hepatitis C Virus Polymerase Abolished by Small Molecule Inhibitors Bound to a Novel Allosteric Site. *J. Biol. Chem.* 280, 29765-29770.
66. Harper, S.; Avolio, S.; Pacini, B.; Di Filippo, M.; Altamura, S.; Tomei, L.; Paonessa, G.; Di Marco, S.; Carfi, A.; Giuliano, C.; Padron, J.; Bonelli, F.; Migliaccio, G.; De Francesco, R.; Laufer, Ralph; Rowley, M.; Narjes, F. (2005) Potent Inhibitors of Subgenomic Hepatitis C Virus RNA Replication through Optimization of Indole-N-Acetamide Allosteric Inhibitors of the Viral NS5B Polymerase. *J. Med. Chem.* 48, 4547-4557.
67. Harper, S.; Pacini, B.; Avolio, S.; Di Filippo, M.; Migliaccio, G.; Laufer, R.; De Francesco, R.; Rowley, M.; Narjes, F. (2005) Development and preliminary optimisation of indole N-acetamide inhibitors of the HCV NS5B polymerase. *J. Med. Chem.* 48, 1314-1317.
68. Crawforth, J.; Atack, J. R.; Cook, S. M.; Gibson, K. R.; Nadin, A.; Owens, A. P.; Pike, A.; Rowley, M.; Smith, A. J.; Sohal, B.; Sternfeld, F.; Wafford, K.; Street, L. J. (2004) Tricyclic pyridones as functionally selective human GABAA  $\alpha$ 2/3 receptor-ion channel ligands. *Bioorg. Med. Chem. Lett.* 14, 1679-1682.
69. Tomei, L.; Altamura, S.; Bartholomew, L.; Biroccio, A.; Ceccacci, A.; Pacini, L.; Narjes, F.; Gennari, N.; Bisbocci, M.; Incitti, I.; Orsatti, L.; Harper, S.; Stansfield, I.; Rowley, M.;

- De Francesco, R.; Migliaccio, G. (2003) Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. *J. Virol.* 77, 13225-13231.
70. Gibson, K. R.; Hitzel, L.; Mortishire-Smith, R. J.; Gerhard, U.; Jelley, R. A.; Reeve, A. J.; Rowley, M.; Nadin, A.; Owens, A. P. (2002) Synthesis and Conformational Dynamics of Tricyclic Pyridones Containing a Fused Seven-Membered Ring. *J. Org. Chem.* 67, 9354-9360.
71. Rowley, M. (2002) Some aspects of heterocyclic chemistry in drug discovery. Seminars in Organic Synthesis, 27th Summer School "A. Corbella", Gargnano, Italy.
72. Collins, I.; Moyes, C.; Davey, W. B.; Rowley, M.; Bromidge, F. A.; Quirk, K.; Attack, J. R.; McKernan, R. M.; Thompson, S.-A.; Wafford, K.; Dawson, G. R.; Pike, A.; Sohal, B.; Tsou, N. N.; Ball, R. G.; Castro, J. L. (2002) 3-Heteroaryl-2-pyridones: Benzodiazepine Site Ligands with Functional Selectivity for  $\alpha 2/\alpha 3$ -Subtypes of Human GABAA Receptor-Ion Channels. *J. Med. Chem.*, 45, 1887-1900.
73. Gibson, K.R.; Thomas, S. R.; Rowley, M. (2001) An intramolecular sulfoxide alkylation-elimination approach to the [1,2,3]triazolo[1,5-a]pyrimidine ring system. *Synlett.* 712-714.
74. Rowley, M.; Hallett, D. J.; Goodacre, S.; Moyes, C.; Crawforth, J.; Sparey, T. J.; Patel, S.; Marwood, R.; Patel, S.; Thomas, S.; Hitzel, L.; O'Connor, D.; Szeto, N.; Castro, J. L.; Hutson, P.H.; MacLeod, A. M. (2001) 3-(4-Fluoropiperidin-3-yl)-2-phenylindoles as High Affinity, Selective and Orally Bioavailable h5HT<sub>2A</sub> Receptor Antagonists. *J. Med. Chem.* 44, 1603-1614
75. Rowley, M.; Bristow, L.; Hutson, P. (2001) Perspective: Current and novel approaches to the drug treatment of schizophrenia. *J. Med. Chem.* 44, 477-501
76. Crawforth, J.; Goodacre, S.; Maxey, R.; Bourrain, S.; Patel, S.; Marwood, R.; O'Connor, D.; Herbert, R.; Hutson, P.; Rowley, M. (2000) 3-(4-Piperidinyl)- and 3-(8-aza-bicyclo[3.2.1]oct-3-yl)-2-phenyl-1*H*-indoles as bioavailable h5-HT<sub>2A</sub> antagonists. *Bioorg. Med. Chem. Lett.* 10, 2701-3
77. Hallett, D. J.; Gerhard, U.; Goodacre, S. C.; Hitzel, L.; Sparey, T. J.; Thomas, S.; Rowley M.; Ball R. G. (2000) Neighboring group participation of the indole nucleus: an unusual DAST-mediated rearrangement reaction. *J. Org. Chem.* 65, 4984.
78. Collins, I.; Davey, W. B.; Rowley, M.; Quirk, K.; Bromidge, F. A.; McKernan, R. M.; Thompson, S.-A.; Wafford, K. A. (2000) N-(Indol-3-ylglyoxylyl)piperidines: high affinity agonists of human GABA-A receptors containing the  $\alpha 1$  subunit. *Bioorg. Med. Chem. Lett.* 10, 1381-1384.
79. Ahmed, A.; Clayden, J.; Rowley, M. (1999) 1,3,4,5-Tetrahydroazepin-2-ones by dearomatizing anionic cyclisation of N-allyl-1-naphthamides. *Synlett.* 12, 1954-1956.
80. van Niel, M. B.; Collins, I.; Beer, M. S.; Broughton, H. B.; Cheng, S. K. F.; Goodacre, S. C.; Heald, A.; Locker, K. L.; MacLeod, A. M.; Morrison, D.; Moyes, C. R.; O'Connor, D.; Pike, A.; Rowley, M.; Russell, M. G. N.; Sohal, B.; Stanton, J. A.; Thomas, S.; Verrier, H.; Watt, A. P.; Castro, J. L. (1999) Fluorination of 3-(3-(Piperidin-1-yl)propyl)indoles and 3-(3-(1-piperazinyl)propyl)indoles Gives Selective Human 5-HT<sub>1D</sub>



Receptor Ligands with Improved Pharmacokinetic Profiles. *J. Med. Chem.*, 42, 2087-2104.

81. Moore, K. W.; Bonner, K.; Jones, E. A.; Emms, F.; Leeson, P. D.; Marwood, R.; Patel, S.; Patel, S.; Rowley, M.; Thomas, S.; Carling, R. W. (1999) 4-N-linked-heterocyclic piperidine derivatives with high affinity and selectivity for human dopamine D4 receptors. *Bioorg. Med. Chem. Lett.* 9, 1285-1290.
82. Ahmed, A.; Clayden, J.; Rowley, M. (1998) Anion translocation in organolithiums: a mechanism for the lithiation and cyclization of tertiary naphthamides. *Tet. Lett.* 39, 6103-6106.
83. Bourrain, S.; Collins, I.; Neduvellil, J. G.; Rowley, M.; Leeson, P. D.; Patel, S.; Patel, S.; Emms, F.; Marwood, R.; Chapman, K. L.; Fletcher, A. E.; Showell, G. A. (1998) Substituted pyrazoles as novel selective ligands for the human dopamine D4 receptor. *Bioorg. Med. Chem.* 6, 1731-1743.
84. Collins, I.; Rowley, M.; Davey, M. B.; Emms, F.; Marwood, R.; Patel, S.; Patel, S.; Fletcher, A.; Ragan, I. C.; Leeson, P. D.; Scott, A. L.; Broten, T. (1998) 3-(1-Piperazinyl)-4,5-dihydro-1H-benzo[g]indazoles: high affinity ligands for the human dopamine D4 receptor with improved selectivity over ion channels. *Bioorg. Med. Chem.* 6, 1655.
85. Ahmed, A.; Clayden, J.; Rowley, M. (1998) Anionic cyclizations of an N-benzyl naphthamide: a route to benz[e]isoindolones. *J. Chem. Soc., Chem. Commun.* 297-298.
86. Rowley, M.; Kulagowski, J. J.; Watt, A. P.; Rathbone, D.; Stevenson, G. I.; Carling, R. W.; Baker, R.; Marshall, G. R.; Kemp, J. A.; Foster, A. C.; Grimwood, S.; Hargreaves, R.; Hurley, C.; Saywell, K. L.; Leeson, P. D. (1997) The Effect of Plasma Protein Binding on *In Vivo* Activity and Brain Penetration in Glycine/NMDA Receptor Antagonists. *J. Med. Chem.*, 40, 4053-4068.
87. Rowley, M.; Collins, I.; Broughton, H.B.; Davey, W.B.; Baker, R.; Emms, F.; Marwood, R.; Patel, S.; Patel, S.; Ragan, C.I.; Freedman, S.B.; Ball R., Leeson. P.D. (1997) 4-Heterocyclylpiperidines as Selective High Affinity Ligands at the Human Dopamine D4 Receptor. *J. Med. Chem.*, 40, 2374-2385.
88. Pernia, G. J.; Kilburn, J D.; Essex, J. W.; Mortishire-Smith, R. J.; Rowley, M. (1996). Stabilization of a Cis Amide Bond in a Host-Guest Complex. *J. Am. Chem. Soc.* 118, 10220-10227.
89. Curtis, N. R.; Kulagowski, J. J.; Leeson, P. D.; Mawer, I. M.; Ridgill, M. P.; Rowley, M.; Grimwood, S.; Marshall, G. R. (1996). Synthesis and SAR of diiodotyrosine-derived glycine-site N-methyl-D-aspartate receptor ligands. *Bioorg. Med. Chem. Lett.* 6, 1145-1150.
90. Rowley, M.; Broughton, H. B.; Collins, I.; Baker, R.; Emms, F.; Marwood, R.; Patel, S.; Patel, S.; Ragan, C.I.; Leeson P.D. (1996). 5-(4-Chlorophenyl)-4-methyl-3-(1-(2-phenylethyl)piperidin-4-yl)isoxazole: A Potent, Selective Antagonist at Human Cloned Dopamine D4 Receptors. *J. Med. Chem.* 39, 1943-5.
91. Rowley, M.; Leeson, P.D.; Grimwood, S.; Marshall, G.; Saywell, K. (1995). 5,6,7,8-Tetrahydroquinolones as antagonists at the glycine site of the NMDA receptor. *Bioorg. Med. Chem. Lett.* 5, 2089-92.

92. Grimwood, S.; Kulagowski, J. J.; Mawer, I. M.; Rowley, M.; Leeson, P. D.; Foster, A. C. (1995). Allosteric modulation of the glutamate site on the NMDA receptor by four novel glycine site antagonists. *Eur. J. Pharmacol.* 290, 221-6.
93. Pernia, G. J.; Kilburn, J. D.; Rowley, M. (1995). A novel receptor for amino acid derivatives. *J. Chem. Soc., Chem. Commun.* 305-6.
94. Tricklebank, M. D.; Bristow, L. J.; Hutson, P. H.; Leeson, P. D.; Rowley, M.; Saywell, K.; Singh, L.; Tattersall, F. D.; Thorn, L.; Williams, B. J. (1994). The anticonvulsant and behavioral profile of L-687,414, a partial agonist acting at the glycine modulatory site on the N-methyl-D-aspartate (NMDA) receptor complex. *Br. J. Pharmacol.* 113, 729-36.
95. Kulagowski, J. J.; Baker, R.; Curtis, N. R.; Mawer, I. M.; Moseley, A. M.; Ridgill, M. P.; Rowley, M.; Stansfield, I.; Leeson, P. D. (1994). 3'-(Arylmethyl)- and 3'-(Aryloxy)-3-phenyl-4-hydroxyquinolin-2(1H)-ones: Orally Active Antagonists of the Glycine Site on the NMDA Receptor. *J. Med. Chem.* 37, 1402-5.
96. Leeson, P.D.; Baker, R.; Carling R.W.; Kulagowski J.J.; Mawer I.M.; Ridgill M.P.; Rowley M.; Smith J.A.; Stansfield I.; Stevenson G.I.; Foster A.C.; Kemp J.A. (1993). Amino acid bioisosteres: Design of 2-quinolone derivatives as glycine-site N-methyl-D-Aspartate receptor antagonists. *Bioorg. Med. Chem. Lett.* 3, 299-304.
97. Rowley, M.; Leeson, P. D.; Stevenson, G. I.; Moseley, A. M.; Stansfield, I.; Sanderson, I.; Robinson, L.; Baker, R.; Kemp, J. A. (1993). 3-Acyl-4-hydroxyquinolin-2(1H)-ones. Systemically active anticonvulsants acting by antagonism at the glycine site of the N-methyl-D-aspartate receptor complex. *J. Med. Chem.*, 36, 3386-96.
98. Leeson, P. D.; Carling, R. W.; Kulagowski, J. J.; Mawer, I. M.; Moore, K. W.; Moseley, A. M.; Rowley, M.; Smith, J. D.; Stevenson, G. I. (1993). Drugs interacting with the glycine binding site. *Perspect. Med. Chem.* 239-57. Editor(s): Testa, Bernard.
99. Leeson, P.D.; Williams B.J.; Rowley M.; Moore K.W.; Baker R.; Kemp J.A.; Priestley T.; Foster A.C.; Donald A.E. (1993). Derivatives of 1-hydroxy-3-aminopyrrolidin-2-one (HA966). Partial agonists at the glycine site of the NMDA receptor. *Bioorg. Med. Chem. Lett.* 3, 71-76
100. Rowley, M.; Leeson P.D.; Grimwood S.; Foster A.; Saywell K. (1992). 2-carboxyindolines and indoles as potential glycine/NMDA antagonists: Effects of five membered ring conformation on affinity. *Bioorg. Med. Chem. Lett.* 2, 1627-1630
101. Rowley, M.; Leeson P.D.; Williams B.J.; Moore K.W. and Baker R. (1992). Routes to 4-substituted analogues of the glycine/NMDA antagonist HA-966. Enantioselective synthesis of (3R,4R) 3-Amino-1-Hydroxy-4-methyl-2-pyrrolidinone (L-687,414). *Tetrahedron* 3557.
102. Leeson, P. D.; Carling, R. W.; Williams, B.J.; Baker, R.; Ladduwahetty, T.; Moore, K. W.; Rowley, M.; Foster, A. C.; Kemp, J. A. (1992). Non-competitive N-methyl-D-aspartate antagonists; structure-activity relationships for compounds acting at the ion channel and glycine sites. *Trends Med. Chem.* '90, *Proc. Int. Symp. Med. Chem.* 11th, 169-74. Editor(s): Sarel, Shalom; Mechoulam, Raphael; Agranat, Israel.
103. Leeson, P.D.; Carling R.W.; Williams B.J.; Baker R.; Ladduwahetty T.; Moore K.W.; Rowley M.; Foster A.C.; Kemp J.A.; Tricklebank M.D. (1992). Non-competitive N-methyl-D-aspartate antagonists: Structure Activity Relationships for compounds acting at

- the ion channel and glycine sites. *Trends in Medicinal Chemistry '90*, Sarel S (Ed) Blackwell Scientific Publications, Oxford, 169-174.
104. Rowley, M. and Leeson P.D. (1992). Excitatory Amino Acid Antagonists. *Current Opinion in Therapeutic Patents* 2, 1201.
  105. Stevenson G.I.; Leeson P.D.; Rowley M.; Sanderson I. and Stansfield I. (1992). Synthesis of *cis* and *trans* 4-Amido 2-Carboxytetrahydroquinolines, high affinity ligands at the glycine site of the NMDA Receptor. *Bioorg. Med. Chem. Lett.* 2, 371.
  106. Leeson, P.D.; Williams B.J.; Baker R.; Ladduwahetty T.; Moore K.W. and Rowley M. (1990). Effects of Five-Membered Ring Conformation on Bioreceptor Recognition: Identification of 3*R*-Amino-1-Hydroxy-4*R*-Methylpyrrolidin-2-One (L-687,414) as a Potent Glycine/N-Methyl- D-Aspartate Receptor Antagonist. *J. Chem. Soc., Chem. Commun.* 1578.
  107. Rowley, M.; Masamitsu, T.; Kishi, Y (1989). Total Synthesis of Ophiobolin C. *J. Am. Chem. Soc.* 111, 2735.
  108. Fleming, I.; Rowley, M.; Cuadrado, P.; González-Nogal, A.M.; Pulido, F.J. (1989). The Silyl-Cupration and Stannyl-Cupration of Allenes. *Tetrahedron* 413.
  109. Rowley, M.; Kishi, Y. (1988). Synthetic Studies on Ophiobolins. *Tet. Lett.* 4909.
  110. Fleming, I.; Rowley, M. (1987). A Regiocontrolled Synthesis of Allylstannanes. *J. Chem. Soc., Perkin I* 2259.
  111. Fleming, I.; Rowley, M. (1986). A Regiocontrolled Synthesis of Allylstannanes. *Tet. Lett.* 5417.
  112. Fleming, I.; Rowley, M. (1986). The Stereochemistry of the Intramolecular Attack of an Aldehyde on a Carbon-Tin Bond. *Tetrahedron* 3181.
  113. Fleming, I.; Rowley, M. (1985). The Stereochemistry of Attack by a Carbon Electrophile on a Tin-Carbon Bond. *Tet. Lett.* 3857.

## PATENTS

1. Dioxotetrahydroquinolines. EP 0459561 (1991)
2. Hydroxyquinolone derivatives. EP 0481676 (1992)
3. 2(1H)-Quinolone Derivatives. WO 9310783 (1993)
4. 3-Phenyl-2(1H)-quinolone derivatives. WO 9311115 (1993)
5. (Piperidiny)pyrazoles and analogs. WO 9410145 (1994)
6. Dopamine receptor subtype ligands. WO 9410162 (1994)
7. Pyrimidine derivatives for treatment of dopamine disorders. WO 9426733 (1994)
8. Fused tricyclic heteroaromatic derivatives. WO 9507893 (1995)
9. Fused tricyclic heteroaromatic derivatives. WO 9507262 (1995)
10. Piperazine, piperidine and tetrahydropyridine derivatives. WO 9718203 (1997)
11. Substituted piperidine derivatives as selective agonists of 5-HT receptors. WO 9718202 (1997)
12. Indolylalkyl piperazines as selective 5-HT<sub>1</sub> agonists. WO 9719943 (1997)
13. Preparation of heteroarylpyridones as GABAA  $\alpha$ <sub>2</sub>/ $\alpha$ <sub>3</sub> ligands. WO 9855480 (1998)
14. Preparation of phenylindoles as 5-HT<sub>2A</sub> receptor ligands. WO 9911619 (1999)
15. Preparation of 3-(piperidin-4-yl)-2-phenylindoles as 5-HT<sub>2A</sub> receptor antagonists. WO 9911641 (1999)
16. Preparation of 3-(piperidin-3-yl)-1H-indole derivatives as 5-HT<sub>2A</sub> receptor antagonists for treatment of psychotic disorders such as schizophrenia. WO 9947511 (1999)
17. Preparation of triazolopyrimidines as ligands for GABA receptors. WO 9965907 (1999)
18. Preparation of 3-azabicyclooctyl-2-phenylindoles as selective antagonists of 5-HT<sub>2A</sub> receptors. WO 0004017 (2000)
19. Preparation of phenylindoles as 5-HT<sub>2A</sub> receptor ligands. WO 0005229 (2000)
20. Imidazotriazine derivatives as ligands for GABA receptors. WO 0114377(2001)
21. Preparation of imidazopyridines as GABAA receptor ligands. WO 0118000 (2001)
22. Preparation of 3-phenylimidazo[1,2-a]pyridines as ligands for GABA receptors. WO 0138326 (2001)
23. Preparation of tricyclic pyridin-2-one analogue as a GABA receptor ligand. US 010053776 (2001)
24. Preparation of tricyclic pyridin-2-one analogues as ligands for GABAA receptors. WO 03016311 (2003)
25. Preparation of tricyclic pyridin-2-one analogues as ligands for GABAA receptors. WO 03018546 (2003)
26. Preparation of tricyclic pyridin-2-one analogues as GABAA receptor ligands. WO 03024964 (2003)
27. Preparation of N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase. WO 03035077 (2003)
28. Preparation of tetrahydro-4H-pyrido[1,2-a]pyrimidines and related compounds as HIV integrase inhibitors. WO 04058756 (2004)
29. A preparation of tetrahydro-4H-pyrido[1,2-a]pyrimidine derivatives, useful as HIV integrase inhibitors. WO 04058757 (2004)
30. Preparation of indole acetamides as inhibitors of the hepatitis c virus NS5B polymerase. WO 04087714 (2004)
31. Antiviral therapeutic compound. IT 2004RM0414 (2004)
32. Thienopyrroles as antiviral agents. WO 05023819 (2005)
33. Indoles and azaindoles as antiviral agents. WO 05034941 (2005)
34. Preparation of amino acid amide derivatives as inhibitors of histone deacetylase. WO 06005941 (2006)
35. Preparation of naphthalimide derivatives as antiviral agents. WO 06027628 (2006)
36. Preparation of tetracyclic indole derivatives as antiviral agents for hepatitis C. WO 06046039 (2006)
37. Preparation of tetracyclic indole derivatives as antiviral agents. WO 06046030 (2006)

38. Preparation of heterocycle derivatives as histone deacetylase inhibitors. WO 06061638 (2006)
39. Preparation of peptidyl macrocyclic compounds as antiviral agents. WO 07148135 (2007)
40. Preparation of tetracyclic indole derivatives as antiviral agents. WO 07054741 (2007)
41. Compositions useful for the treatment of viral diseases. WO 2013066753 (2013)
42. Preparation of heterocyclic acrylamides as mitochondrial permeability transition pore inhibitors and uses thereof. WO 2022049376 (2022)